S&P 500
7,582.20
+0.03%
Dow Jones
51,018.80
+0.58%
Nasdaq 100
30,344.40
+0.25%
Russell 2000
2,916.31
-0.54%
FTSE 100
10,378.60
-0.32%
Nikkei 225
66,231.90
+0.67%

Health and Healthcare

Array BioPharma Slides on Secondary Offering

Photo of Chris Lange
By Chris Lange Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Array BioPharma Slides on Secondary Offering

© Thinkstock

Array BioPharma Inc. (NASDAQ: ARRY) saw its shares turn negative early on Thursday after the firm announced a secondary offering. The company offered no pricing details, but it does value the offering up to $175 million, with an overallotment option for an additional $26.25 million.

The underwriters for the offering are JPMorgan, Cowen and Piper Jaffray.

For some quick background: this is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer.

The firm has eight registration studies that are currently advancing related to seven Array-owned or partnered drugs: binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Cascadian Therapeutics).

[nativounit]

In the filing, the company said:

We intend to use the net proceeds from this offering to fund our research and development efforts, including clinical trials for our proprietary candidates, build and scale commercial capability, and for general corporate purposes, including general working capital purposes. We may also use a portion of the net proceeds to acquire or invest in complementary businesses, technologies, drugs, drug candidates or other intellectual property, although we have no present commitments or agreements to do so.

Shares of Array closed Wednesday up 5.6% at $10.53, with a consensus analyst price target of $14.56 and a 52-week range of $3.45 to $13.40. Following the release, the stock was initially down 6.7% at $9.82 in early trading indications Thursday.

[wallst_email_signup]

DISCLOSURE:
INVESTMENTS ARE NOT FDIC INSURED • ARE NOT BANK GUARANTEED • MAY LOSE VALUE Brokerage and Active investing products offered through SoFi Securities LLC, member FINRA(www.finra.org)/SIPC(www.sipc.org). Advisory services are offered by SoFi Wealth LLC, an SEC-registered investment adviser. Information about SoFi Wealth’s advisory operations, services, and fees is set forth in SoFi Wealth’s current Form ADV Part 2 (Brochure), a copy of which is available upon request and at www.adviserinfo.sec.gov. Probability of Member receiving $1,000 is a probability of 0.026%; If you don’t make a selection in 30 days, you’ll no longer qualify for the promo. Customer must fund their account with a minimum of $50.00 to qualify. Other fees, such as exchange fees, may apply. Please view our fee disclosure to view a full listing of fees. Investing in alternative investments and/or strategies may not be suitable for all investors and involves unique risks, including the risk of loss. An investor should consider their individual circumstances and any investment information, such as a prospectus, prior to investing. Interval Funds are illiquid instruments, the ability to trade on your timeline may be restricted. Brokerage and Active investing products offered through SoFi Securities LLC, Member FINRA(www.finra.org) /SIPC(www.sipc.org). There are limitations with fractional shares to consider before investing. During market hours fractional share orders are transmitted immediately in the order received. There may be system delays from receipt of your order until execution and market conditions may adversely impact execution prices. Outside of market hours orders are received on a not held basis and will be aggregated for each security then executed in the morning trade window of the next business day at market open. Share will be delivered at an average price received for executing the securities through a single batched order. Fractional shares may not be transferred to another firm. Fractional shares will be sold when a transfer or closure request is initiated. Please consider that selling securities is a taxable event. Options involve risks, including substantial risk of loss and the possibility an investor may lose the entire investment Before trading options please review the Characteristics and Risks of Standardized Options  Investing in an Initial Public Offering (IPO) involves substantial risk, including the risk of loss. Further, there are a variety of risk factors to consider when investing in an IPO, including but not limited to, unproven management, significant debt, and lack of operating history. For a comprehensive discussion of these risks please refer to SoFi Securities’ IPO Risk Disclosure Statement This should not be considered a recommendation to participate in IPOs and investors should carefully read the offering prospectus to determine whether an offering is consistent with their investment objectives, risk tolerance, and financial situation. New offerings generally have high demand and there are a limited number of shares available for distribution to participants. Many customers may not be allocated shares and share allocations may be significantly smaller than the shares requested in the customer’s initial offer (Indication of Interest). For more information on the allocation process please visit IPO Allocation.
Follow 24/7 Wall St. on Google
Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Continue Reading

Recro Pharma Secondary Offering (UPDATE)
Chris Lange |

Recro Pharma Secondary Offering (UPDATE)

Recro Pharma intends to offer more than 5 million shares at $6.99 apiece in a secondary offering valued at roughly…

Achaogen Prices Secondary Offering
Chris Lange |

Achaogen Prices Secondary Offering

Achaogen has priced its more than 6 million share offering at $13.50 per share in a secondary offering valued up…

Zai Lab Announces Potential Pricing for IPO
Chris Lange |

Zai Lab Announces Potential Pricing for IPO

Biopharmaceutical company Zai Lab intends to price its 8 million shares in the range that results in an initial public…

Achaogen Gears Up for Secondary Offering
Chris Lange |

Achaogen Gears Up for Secondary Offering

Achaogen, Inc. (NASDAQ: AKAO) saw its shares continue to rise late on Tuesday after the company reported that it would…

Agios Files for Secondary Offering
Chris Lange |

Agios Files for Secondary Offering

Agios Pharmaceuticals has filed with the SEC regarding a secondary offering of up to $150 million of its common stock.

Hutchinson China MediTech Sets Price for US IPO
Chris Lange |

Hutchinson China MediTech Sets Price for US IPO

Hutchinson China MediTech will offer more than 7 million American depositary shares at $13.50 apiece in and IPO valued at…

Celator Pharma Prices Secondary Offering
Chris Lange |

Celator Pharma Prices Secondary Offering

Celator Pharmaceuticals has filed with the U.S. Securities and Exchange Commission (SEC) for a secondary offering.

Idera Pharmaceuticals Sinks on Secondary Offering
Chris Lange |

Idera Pharmaceuticals Sinks on Secondary Offering

Shares of Idera Pharmaceuticals sank on Thursday after the company announced that it intends to have a secondary offering.

Chris Lange |

RegenXBio Updates Anticipated Price for IPO

This is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy.

Top Gaining Stocks

Dell Technologies
DELL • Vol: 42,366,555
NetApp
NTAP • Vol: 15,911,807
ServiceNow
NOW • Vol: 68,243,561
IBM
IBM • Vol: 28,527,546
Hewlett Packard Enterprise
HPE • Vol: 86,996,387

Top Losing Stocks

Coterra Energy
CTRA • Vol: 73,319,495
Clorox
CLX • Vol: 4,744,001
ResMed
RMD • Vol: 3,526,686
Intel
INTC • Vol: 191,680,425
Skyworks Solutions
SWKS • Vol: 5,407,806